Dr. Kim

Lyndon J. Kim, MD

Contact Dr. Kim

900 Walnut Street
Suite 200
Philadelphia, PA 19107

(215) 955-7000

Most Recent Peer-reviewed Publications

  1. Rethinking medulloblastoma from a targeted therapeutics perspective
  2. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design
  3. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
  4. Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0)
  5. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment
  6. Ependymomas overexpress chemoresistance and DNA repairrelated proteins
  7. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244
  8. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
  9. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas
  10. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better
  11. A phase 2 trial of verubulin for recurrent glioblastoma: A prospective study by the brain tumor investigational consortium (BTIC)
  12. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
  13. The potential role of magnetic resonance spectroscopy in image-guided radiotherapy
  14. Chemoirradiation for Glioblastoma Multiforme: The National Cancer Institute Experience
  15. Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: Prognosis and identification by111indium-octreotide imaging
  16. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas
  17. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
  18. Primary brain tumors: Characteristics, practical diagnostic and treatment approaches
  19. A phase I trial of enzastaurin in patients with recurrent gliomas
  20. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma